Cardiovascular disease is the most common cause of death worldwide, and hypertension is the major risk factor 1 . Mendelian hypertension elucidates mechanisms of blood pressure regulation. Here we report six missense mutations in PDE3A (encoding phosphodiesterase 3A) in six unrelated families with mendelian hypertension and brachydactyly type E (HTNB) 2 . The syndrome features brachydactyly type E (BDE), severe salt-independent but age-dependent hypertension, an increased fibroblast growth rate, neurovascular contact at the rostral-ventrolateral medulla, altered baroreflex blood pressure regulation and death from stroke before age 50 years when untreated 3,4 . In vitro analyses of mesenchymal stem cell-derived vascular smooth muscle cells (VSMCs) and chondrocytes provided insights into molecular pathogenesis. The mutations increased protein kinase A-mediated PDE3A phosphorylation and resulted in gain of function, with increased cAMP-hydrolytic activity and enhanced cell proliferation. Levels of phosphorylated VASP were diminished, and PTHrP levels were dysregulated. We suggest that the identified PDE3A mutations cause the syndrome. VSMC-expressed PDE3A deserves scrutiny as a therapeutic target for the treatment of hypertension. The mendelian hypertension syndromes described thus far involve increased sodium reabsorption in the distal nephron 5 . The sole exception is autosomal dominant hypertension with BDE (HTNB; MIM 112410), first reported in a Turkish kindred 2,6 . HTNB was linked to chromosome 12p in six unrelated families 2,7,8 . The locus accounts for a difference of ~50 mm Hg in mean blood pressure at age 50 years 2 . Penetrance is 100% (Fig. 1) . Previously, we reported a rearrangement on chromosome 12p shared by all affected families 8,9 . A linkage study in Chinese hypertensive families without BDE identified a linkage signal coinciding with the HTNB locus, supporting the relevance of this locus to essential hypertension 10 .
The mendelian hypertension syndromes described thus far involve increased sodium reabsorption in the distal nephron 5 . The sole exception is autosomal dominant hypertension with BDE (HTNB; MIM 112410), first reported in a Turkish kindred 2, 6 . HTNB was linked to chromosome 12p in six unrelated families 2, 7, 8 . The locus accounts for a difference of ~50 mm Hg in mean blood pressure at age 50 years 2 . Penetrance is 100% (Fig. 1) . Previously, we reported a rearrangement on chromosome 12p shared by all affected families 8, 9 . A linkage study in Chinese hypertensive families without BDE identified a linkage signal coinciding with the HTNB locus, supporting the relevance of this locus to essential hypertension 10 .
We performed whole-genome sequencing of Turkish family members and identified a heterozygous missense mutation in PDE3A (NCBI Gene 5139), which encodes a cyclic GMP (cGMP) and AMP (cAMP) phosphodiesterase with a prominent role in the heart, VSMCs, oocytes and platelets 11 . Resequencing of all 48 affected individuals in 6 unrelated families identified 6 independently clustered heterozygous missense mutations in exon 4 of PDE3A. The altered amino acids, residues 445, 447 and 449, belong to a highly conserved PDE3A domain ( Figs. 1 and 2a, Supplementary Fig. 1 and Supplementary Table 1) .
We detected none of the previously described chromosomal breakpoints on chromosome 12p12.2-12.1, perhaps owing to high repetitive content in the breakpoint regions ( Fig. 2a and Supplementary  Table 2 ) 8, 9 . We noted intrafamilial phenotypic variability, with an affected individual (VI/9; 145/77 mm Hg (diastolic/systolic blood pressure)) showing only mild BDE and height (159 cm) in the 30th percentile in comparison to one of his severely affected cousins (142 cm, first percentile; VI/1; Fig. 2b ) 7 . Magnetic resonance imaging (MRI) identified a posterior inferior cerebellar artery (PICA) loop ( Supplementary Fig. 2 ) 4 . Haplotype analysis detected a new recombination event that reduced the size of the linkage interval and eliminated an inversion common to all affected individuals in the six families (Fig. 2c) 9 . In contrast, the affected mother's haplotype showed cosegregation with the more severe brachydactyly phenotype.
PDE proteins are involved during early stages of osteogenesis 12 . PDE4D mutations have been associated with severe brachydactyly in acrodysostosis 13, 14 . In mice, Pde3a is expressed in the developing limbs, consistent with a role during chondrogenesis ( Fig. 2d and Supplementary Fig. 3a,b) . Chondrogenic downregulation of expression of the PTHLH gene, encoding the parathyroid hormone-related peptide PTHrP, was associated with BDE 15 . We also observed PTHLH downregulation in chondrogenically induced fibroblasts from affected individuals ( Fig. 2e and Supplementary Fig. 3c) .
We addressed the functional consequences of the identified PDE3A mutations in HeLa cells expressing the mutant proteins. Forskolin and l-arginine stimulate adenylate and guanylate cyclases, respectively, to enhance cellular cAMP and cGMP levels 16, 17 . We detected significantly reduced cAMP levels in comparison to wild-type PDE3A (P ≤ 0.001), consistent with gain-of-function mutations, with no change in cGMP levels ( Supplementary Fig. 4a,b) . Three PDE3A isoforms-PDE3A1 (microsomal), PDE3A2 and PDE3A3 (both microsomal and cytosolic)-have been identified in human myocardium 18, 19 . PDE3A3 does not contain the sequence harboring the altered residues. The predominant isoform in VSMCs is PDE3A2 (refs. 18,20) . To directly elucidate the effects of the mutations, we compared the Michaelis-Menten kinetics of cAMP-hydrolytic activity for recombinant Flag-tagged wild-type and Thr445Asn PDE3A1 and for wild-type and Thr445Asn PDE3A2 purified from transfected cells (Fig. 3a,b and Supplementary Fig. 4d-k) . The p.Thr445Asn alteration increased the affinity (decreased the K M ) of both PDE3A1 and PDE3A2 for cAMP without affecting V max (the maximum catalytic velocity of the substrate-saturated enzyme). This increase in affinity relative to the wild-type enzyme was enhanced for both isoforms l e t t e r s when cAMP-mediated signaling was stimulated by exposure of the transfected cells to forskolin. Half-maximal inhibitory concentration (IC 50 ) measurements for milrinone, a PDE3 inhibitor used to augment cardiac contractility and decrease vascular resistance in patients with heart failure 21, 22 , showed that higher concentrations of the inhibitor were necessary to inhibit the recombinant Thr445Asn forms of both PDE3A1 and PDE3A2 (Fig. 3c,d) , whereas the IC 50 values for cGMP inhibition of cAMP-hydrolytic activity were nearly equivalent for the wild-type and mutant isoforms (Supplementary Fig. 5) .
We also used a vector with the luciferase gene under the control of a cAMP-responsive element (CRE) to determine the effects of all six PDE3A mutations on cAMP-mediated signaling in cells 23 . Consistent with the observed gain-of-function effects from increased cAMP-hydrolytic activity, the expression of all six PDE3A mutants decreased luciferase expression in comparison to wild-type PDE3A (Supplementary Fig. 6 ).
We obtained mesenchymal stem cells (MSCs) from two affected individuals with the p.Thr445Asn alteration (VI/9 and VI/17). MSCs were characterized by FACS and differentiated into adipocytes, osteocytes and chondrocytes, demonstrating their multilineage potential ( Supplementary Fig. 7a,b) 24 . MSC-derived VSMCs expressed smooth muscle actin α (SMAα), calponin and transgelin at high levels (SM22α; Supplementary Fig. 7c ). Deletion of mouse Pde3a suppressed VSMC proliferation, indicating the importance of PDE3A during arteriogenesis and arterial remodeling 25 . Therefore, we focused on the vascular relevance of the PDE3A mutations. In our earlier studies, we had observed an enhanced cell growth rate for fibroblasts and hyperplastic arterial walls from affected individuals, concerning the thickened VSMC layer 9, 26 . We hypothesized that the PDE3A mutations were responsible for enhanced mitosis and arterial remodeling. In HeLa cell proliferation assays with full-length PDE3A transfection constructs (encoding PDE3A1 and PDE3A2), as well as in VSMCs derived from patients with the p.Thr445Asn substitution, we observed higher mitotic rates in cells expressing mutant PDE3A. Transfection with vector for wild-type PDE3A also increased cell growth in comparison to endogenous levels of PDE3A (Fig. 3e,f and Supplementary Fig. 8) .
The Ser428 and Ser438 residues that are adjacent to the residues altered by the PDE3A mutations can be phosphorylated by protein kinase C (PKC) or protein kinase A (PKA), causing increased cAMP hydrolysis (Fig. 2a) 18, 27, 28 . Thus, we investigated phosphorylated PDE3A levels without and after exposure to PMA (phorbol-12-myristate-13-acetate; to activate PKC) or forskolin (to increase cAMP content and thereby activate PKA) 29, 30 . Phosphorylation of PDE3A1 Thr445Asn and PDE3A2 Thr445Asn at Ser428 and Ser438 was increased in PMA-and forskolin-treated transfected HeLa cells, in comparison to cells with endogenous protein levels or cells transfected to express wild-type PDE3A (Fig. 4a-e and Supplementary  Fig. 9 ) 19 . Furthermore, in unstimulated MSCs and VSMCs derived from the affected individuals harboring p.Thr445Asn, we detected higher PDE3A Ser428 and Ser438 phosphorylation levels (Fig. 4f,g ). Inhibiting PKA or PKC showed that both kinases phosphorylated PDE3A Ser438 (Supplementary Fig. 10 ). We investigated whether the alteration in PDE3A phosphorylation could be attributed to preferential mRNA expression from the mutated allele. We used pyrosequencing to dissect allele usage and detected no differences between the wild-type and mutated alleles (Supplementary Fig. 11 ). In all affected individuals (black symbols), a PDE3A mutation was found, in contrast to in their unaffected, related family members (white symbols), demonstrating complete penetrance in all families. The nuclear family comprising V/6, V/7 and VI/7-VI/9 was used for the haplotype analysis shown in Figure 2c . X-rays of VI/1 and VI/9 are shown in Figure 2b . MSCs were extracted from VI/9 and VI/17.
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Reduced phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at Ser157, mediated by PKA, has been linked to enhanced VSMC proliferation after angioplasty 31 . Elevated full-length PTHrP levels enhance neointimal proliferation, whereas the PTHrP peptide (residues 1-36) inhibits VSMC proliferation 31, 32 . We observed reduced VASP Ser157 phosphorylation and elevated PTHrP levels in PMA-stimulated HeLa cells expressing the mutant enzymes. VASP Ser157 phosphorylation was not greatly altered in forskolin-treated HeLa cells expressing the mutant enzymes, presumably because the forskolin-induced increase in cAMP levels was sufficient for PKA activation despite hyperactive PDE3A (Fig. 4h) . Moreover, we detected increased expression of full-length PTHrP protein and decreased expression of the PTHrP peptide (residues 1-36) in cells from affected individuals (Supplementary Fig. 12) .
In a peptide SPOT assay, we synthesized 30-mer peptides representing Ile421-Leu450 of wild-type PDE3A and the six mutants, including alanine or aspartic acid replacements for Ser428 and Ser438 (Figs. 2a and 5a, and Supplementary Fig. 13 ) 33 . The spotting of Ser438 or prephosphorylated Ser428 or Ser438, followed by in vitro phosphorylation by PKA, identified significantly enhanced phosphorylation at the PDE3A Ser438 residue of the six mutants, confirming the previous results (Fig. 5a,b and Supplementary Fig. 14a-c) . To further elucidate the increased phosphorylation signal at Ser438 (peptide lanes 7 and 9), we examined whether PKA phosphorylated additional residues. Interestingly, the PKA signals increased even when Ser428 and Ser438 were substituted with alanine residues. This result could be due to increased levels of phosphorylation at Ser439 and Thr440, which are close to Ser438 (Supplementary Fig. 14d-f) .
Finally, we replaced Ser428, Ser438, Ser439 and Thr440 with alanine residues and repeated the Michaelis-Menten kinetic analysis of Flag-tagged wild-type PDE3A1 and PDE3A2 versus the Thr445Asn mutant isoforms. The alanine substitutions diminished cAMP 
(d) Chondrogenic
Pde3a expression in developing mice at 12.5 and 13.5 d was studied by RNA in situ hybridization. Pde3a was expressed in domains involved in digit formation. Scale bars, 1 mm. (e) BDE-associated PTHLH expression was downregulated in chondrogenically induced fibroblasts from six age-and sexmatched affected individuals versus eight unaffected controls (mean ± s.e.m., Wilcoxon-Mann-Whitney rank-sum test, *P = 0.022).
npg l e t t e r s hydrolysis, supporting the notion that mutation-dependent enhanced phosphorylation at these sites is responsible for increased cAMP hydrolysis (Fig. 5c) . We observed that mutant PDE3A was more extensively phosphorylated than wild-type PDE3A at the Ser428 and Ser438 residues and that PTHrP isoforms were dysregulated. Our results suggest that increased PKA-mediated phosphorylation at Ser438 and PKC-mediated phosphorylation at Ser428, reported to increase PDE3A2 activity 27 , may have contributed to the increase in the cAMP-hydrolytic activity of the mutant enzymes, leading to reduced cAMP levels and enhanced cell proliferation. This result would be consistent with the increased affinity of the Thr445Asn mutants for cAMP that we observed after exposure of transfected cells to forskolin (Fig. 3a,b) . Further studies will aim to characterize the possible allosteric effects of these mutations on other phosphorylation sites that may modulate enzyme activity and proteinprotein interactions involved in PDE3A function-for example, the interaction of PDE3A with phospholamban, SERCA2 and AKAP18 described in mouse and human heart [34] [35] [36] .
Augmented full-length PTHrP levels, decreased amounts of PTHrP peptide (residues 1-36) and reduced VASP Ser157 phosphorylation may additionally promote VSMC proliferation in individuals with these gain-of-function PDE3A mutations, leading to vessel wall hyperplasia. The IC 50 measurements showed that a higher milrinone concentration is necessary to abrogate the increased hydrolysis of cAMP by PDE3A1 Thr445Asn and PDE3A2 Thr445Asn. These data are compatible with our previous results indicating that milrinone-induced forearm vasodilation was not significantly different in affected individuals and controls 8 .
Our data strongly suggest that PDE3A mutations in HTNB are responsible for hypertension by contributing to a general increase in peripheral vascular resistance ( Supplementary Fig. 15 ) 2, 26 . The fact that PDE3 inhibition lowers blood pressure in patients with hypertensive heart failure and in patients with pulmonary hypertension is consistent with this hypothesis 37 . cAMP inhibits myosin light chain kinase (MLCK) through phosphorylation of the latter by PKA, thereby causing VSMC relaxation. Dephosphorylation of myosin light chains by MLC phosphatase also produces relaxation 38 . Enhanced PDE3A activity could, by lowering the intracellular cAMP concentration in VSMCs, promote increased peripheral vascular constriction. Furthermore, increased VSMC proliferation could induce remodeling , V max and K M values showed that the Thr445Asn mutant purified from unstimulated and forskolin-stimulated cells (20 µM forskolin for 30 min) had increased cAMP affinity in comparison to wild-type PDE3A (mean ± s.e.m.; n = 3). pSer438, phosphorylation at Ser438. (c) For the milrinone inhibitor, the IC 50 value for wild-type PDE3A1 was 1.12 × 10 −4 µM, in contrast to 0.234 µM for the Thr445Asn mutant (n = 3). (d) For wild-type PDE3A2, the IC 50 for milrinone was 0.0034 µM, in comparison to 1.242 µM for PDE3A2 Thr445Asn (n = 2). (e) A proliferation assay showed an increased mitosis rate with all six PDE3A mutants in comparison to wild-type PDE3A after expression in HeLa cells (mean ± s.e.m.; n = 3; normalized to the endogenous PDE3A levels of mock-transfected control; Wilcoxon-Mann-Whitney rank-sum test, **P < 0.01, *P < 0.05). The difference in cell numbers between cells expressing mutant and wild-type PDE3A was a modest 6.2% with a maximum of 9.5%. (f) Proliferation assay of two patient-derived VSMC lineages (affected) and two control lineages (unaffected). The patient-derived VSMCs proliferated faster than the controls: the doubling time (t d ) for control cells was 36.3 h and was 30.2 h for patient-derived cells (mean ± s.e.m.; n = 3; Wilcoxon-Mann-Whitney test, *P = 0.05). The results for the functional assays in this figure are from biological replicates.
npg l e t t e r s favoring hypertension, perhaps by changes in vascular structure or neurovascular contact. Our studies of PDE3A mutants with increased activity showing enhanced mitosis are consistent with the observed decrease in VSMC proliferation when Pde3a was deleted in an earlier study 25 .
The milder BDE of subject VI/9 suggests that regulatory DNA elements or noncoding RNAs in the excluded inversion region epigenetically trigger the pathogenesis of BDE and short stature. We found that PDE3A, which is involved in mouse chondrogenesis, could contribute to PTHLH downregulation, which has been associated with BDE 15, 39 . In chondrocytes, PTHrP is regulated by cAMP and transduces signals through the PTH/PTHrP receptor, activating adenylate cyclase for cAMP production 40, 41 . We suggest that increased cAMP hydrolysis could cause PTHrP downregulation through a regulatory feedback loop (Supplementary Fig. 15 ).
In conclusion, we have identified independently clustered PDE3A mutations in individuals with HTNB, which exhibit a gain-of-function effect on cAMP hydrolysis. We found evidence for mechanisms mediating VSMC hyperplasia and increased peripheral vascular resistance. Studying the functional consequences of the PDE3A mutations in animal models will result in further insight into normal and pathogenic vascular and skeletal development.
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Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html. The signals for lanes 6, 7 and 9 showed significantly enhanced phosphorylation after incubation with PKA (mean ± s.e.m.; biological replicates, n = 3; two-tailed Wilcoxon-Mann-Whitney rank-sum test, **P < 0.01, *P < 0.05). (c) Michaelis-Menten kinetics of Flag-tagged wild-type PDE3A1, wild-type PDE3A2, PDE3A1 Thr445Asn and PDE3A2 Thr445Asn in comparison to Flag-tagged PDE3A isoforms with alanine substitutions at Ser428, Ser438, Ser439 and Thr440. The alanine substitutions led to a decrease in cAMP hydrolysis (mean ± s.d.; n = 3 biological replicates). The data shown are the ratios of phosphorylated wild-type PDE3A or PDE3A Thr445Asn to the corresponding alanine-substituted isoforms. Immunoblotting verified equal PDE3A amounts during the functional Michaelis-Menten kinetics measurements and diminished Ser438 phosphorylation with the alanine substitutions.
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Study approval, human material. We studied six unrelated families. After approval by the ethics committee (Charité Medical Faculty, Berlin) and written informed consent, we obtained skin fibroblasts from six affected individuals (three male, three female) and eight controls (five male, three female) from the Turkish kindred; mean age was 37.7 ± 0.4 years. We extracted MSCs from two affected Turkish males (VI/9, 17 years old; VI/17, 12 years old) and from two unaffected, non-related controls (male, 15 years old; female, 59 years old).
Whole-genome sequencing, Sanger sequencing and SNP analysis. Complete Genomics performed whole-genome sequencing of three affected patients and one control from a Turkish nuclear family 42 . Whole-genomic DNA was extracted from EDTA-blood using standard procedures. A mean per-sample depth of coverage of 57.39× was reached. After bioinformatic analysis, data were further analyzed with CGA tools. Among the Complete Genomicsannotated variants in coding genes within the linkage interval, only the PDE3A missense mutation resulting in p.Thr445Asn was detected in three affected patients of the Turkish nuclear family. Numerous insertion, deletion or substitution events within the linkage region, indicating micromutations at the putative inversion breakpoints, were found. After excluding annotated SNPs, we selected heterozygous variants that were not detectable in the unaffected control or in the hg19 genome assembly. These variants were further analyzed in a larger cohort (seven affected and seven unaffected individuals; Supplementary Table 1) . Sanger resequencing of the seven affected individuals and seven controls identified only polymorphisms. After identification of the putative inversion breakpoint regions by interphase FISH, the genomic regions with Complete Genomics sequencing reads were further analyzed in the CGI browser (data not shown). Reads for the genomic region of interest were extracted from the Complete Genomics-annotated variants and visualized. None of the variants corresponded to the inversion breakpoints. An Illumina HiSeq 2000 was used to generate 101-bp paired-end reads, and 374 Gb of raw sequence data were mapped to the human reference GRCh37.3 with Novoalign, yielding an average coverage of more than 100-fold. Singlenucleotide variants and small indels were detected with the Genome Analysis Toolkit (GATK) 43 , annotated with ANNOVAR 44 and analyzed on GeneTalk 45 . Structural variants were detected with BreakDancer 46 , and the previously reported inversion was also analyzed as described 47 but did not show any inversion breakpoints.
The primers for exon 4 of PDE3A used to detect the mutations are shown in Supplementary Table 3 . After PCR amplification, amplicons were sequenced using BigDye Terminator Cycle Sequencing Kit v1.1 (Applied Biosystems). Analysis was performed on a 3130xl Genetic Analyzer (Applied Biosystems) using Gene Mapper Software Version 4.0. SeqMan software (Lasergene, Version 10.0; DNAStar) was used to evaluate the traces.
Whole-mount RNA in situ hybridization. In situ hybridizations were carried out using digoxygenin-UTP-labeled sense and antisense riboprobes for mouse Pde3a (coding sequence probe, chr. 6: 141,459,712-141,471,161 bp; 3′ UTR probe, chr. 6: 141,498,908-141,499,348; UCSC Genome Browser, mm10) according to standard protocols. The experiments were approved by the competent local authority in Berlin (LaGeSo).
HeLa cells and chondrogenic induction of fibroblasts.
HeLa cells were ordered from the American Type Culture Collection (ATCC) and grown in DMEM supplemented with 10% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were frequently tested for mycoplasma contamination. Patient-and control-derived fibroblasts were cultured in Eagle's MEM 199 supplemented with 10% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin. The chondrogenic induction of fibroblasts was carried out in pellet cultures with DMEM supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 1× ITS-X (Life Technologies), 10 ng/ml human transforming growth factor (TGF)-β1 (R&D Systems), 500 ng/ml recombinant human insulin-like growth factor (IGF)-1 (R&D Systems), 50 µM l-ascorbic-2-phosphate (Sigma) and l-glutamine (PAA) for 21-28 d. Fibroblasts were fixed for 10 min with 4% paraformaldehyde (Sigma) and stained in 1% Alcian blue (Chroma; 3% acetic acid) for 30 min or in 6% Safranin O (Sigma; in distilled water) for 2 min. Before microscopic documentation, cells were washed twice with 90% ethanol.
Expression plasmids. Each of the six PDE3A mutations were introduced into the full-length cDNA clone for wild-type PDE3A (NM_000921; Origene, SC300151) by in vitro mutagenesis according to the manufacturer's protocol (QuikChange II XL Site-Directed Mutagenesis kit, Ambion Technologies). The recommended PCR extension times were doubled to amplify the large plasmids. In transfected HeLa cells, PDE3A1 translation started at amino acid 146 and PDE3A2 translation was initiated from amino acid 300; PDE3A3 translation could be started from position 484, but this isoform was not expressed in transiently transfected HeLa cells. The mutation encoding p.Thr445Asn was also introduced into expression plasmids encoding Flag-tagged PDE3A1 and PDE3A2 that we had previously characterized 19 . Recombinant Flag-tagged PDE3A1 and PDE3A2 and their mutated versions with alanine substitutions at positions Ser428, Ser438, Ser439 and Thr440 were used in Michaelis-Menten kinetics and IC 50 measurements. Sanger sequencing validated the integrity of the entire PDE3A ORF of each plasmid. cAMP and cGMP enzyme immunoassays. HeLa cells (4.5 × 10 5 ) were seeded in a 6-cm petri dish. After overnight incubation, cells were transfected with 1 pmol of each full-length PDE3A expression plasmid and 20 µl of FuGENE Xtreme Gene HP (Roche) for 48 h. Before cell lysis, stimulation with 20 µM forskolin (Sigma) or 10 µM l-arginine (Sigma) was carried out for 30 min. Cell lysates were used for cAMP and cGMP assays (R&D Systems) that were performed according to the user's manual. BCA-quantified total protein measurements for the cell lysates were used for normalization.
CFSE proliferation assays.
HeLa cells (4 × 10 5 ) or VSMCs (2 × 10 5 ), cultured in 20% FCS, were labeled with CFSE (10 µM per 1 × 10 6 cells) for each time point according to the manufacturer's recommendation (Life Technologies). CFSE-labeled cells were seeded 12-24 h before transfection with 500 fmol of each expression plasmid and 8 µl of FuGENE Xtreme Gene HP. The first flow cytometric measurement of CFSE-labeled cells was performed after overnight incubation and before transfection at time point 0 h. Every 24 h after transfection, cells were analyzed on a BD FACSCalibur flow cytometer. Cell numbers were determined by normalizing the levels of wild-type PDE3A and the six PDE3A mutants to endogenous PDE3A levels of control HeLa cells transfected with empty vector. Differentiation of VSMCs was performed for 14-21 d. VSMC differentiation medium was changed after CFSE labeling to DMEM supplemented with 20% FCS and 1 ng/ml TGF-β1. Proliferation of VSMCs was normalized to cell numbers at the starting point of 0 h.
Immunoprecipitation of Flag-tagged wild-type and Thr445Asn PDE3A1, and PDE3A2 Michaelis-Menten kinetics and IC 50 measurements. Transfected HeLa cells (2 × 10 6 ) transiently expressing Flag-tagged versions of PDE3A1 or PDE3A2 were scraped from two 10-cm cell culture dishes in 1 ml of PBS. Before cell collection, 20 µM forskolin (Sigma) or DMSO (for controls) was used to stimulate cells for 30 min. Quick centrifugation (275g for 5 min at 4 °C) pelleted cells for lysis in 100 µl of RIPA buffer (50 mM Tris, pH 7.8, 10% glycerol, 150 mM NaCl, 1% Triton X, 0.025% sodium deoxycholate and 1 mM EDTA) supplemented with protease and phosphatase inhibitors (Complete and PhosSTOP, Roche Diagnostics). Cells were incubated for 10 min on ice and subsequently centrifuged (21,250g for 15 min at 4 °C; Eppendorf). ANTI-FLAG M2 Magnetic Beads (Sigma-Aldrich) were thoroughly resuspended: 80 µl of beads for each lysate were washed five times in Tris-buffered saline (TBS), mixed thoroughly and placed on a magnetic separator to remove washing buffer. Equilibrated beads were loaded with equal amounts of protein lysate (according to BCA quantification) and incubated overnight at 4 °C on a rotating device. After discarding the supernatant, the beads were washed three times with TBS supplemented with protease and phosphatase inhibitors. Washed beads bound to Flag-tagged PDE3A1 or PDE3A2 proteins were resuspended in 800 µl of incubation buffer (10 mM Tris, pH 8.0 and 10 mM MgCl 2 ), and 10% were used for each cAMP hydrolysis assay. Incubation of purified beads-bound enzymes with increasing concentrations of cAMP or with the milrinone or cGMP inhibitor were carried out at 30 °C and 1,100 rpm for 30 min in a thermomixer. In the inhibitor assays, another incubation at 30 °C and 1,100 rpm for 30 min followed after the addition of 250 nM cAMP as substrate. Tubes were placed in a magnetic separator, and the supernatant was transferred to a new tube filled with neutralization buffer (cAMP Direct Immunoassay kit, Biovision).
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Further steps were performed as described in the instruction manual. The magnetic beads were resuspended in 10× SDS loading buffer (50 mM Tris, pH 6.8, 1.6% SDS, 4% glycerol, 0.6% β-mercaptoethanol and bromophenol blue) and incubated for 5 min at 95 °C. Immunoblotting of each sample was used to validate equal enzyme loading for each condition. The Flag-tagged PDE3A1 and PDE3A2 proteins were detected using antibodies to PDE3A (A302-740A, Bethyl Laboratories) and PDE3A phosphorylated at Ser438 (S442B, University of Dundee). Signals were visualized using Immobilon Western (Merck Millipore) and the Odyssey Fc Dual-Mode Imaging System (Li-Cor). K M and IC 50 values were calculated using GraphPad Prism software (version 5.01). Instead of inaccurate linear regression, we used nonlinear regression analysis with OLS (ordinary least-squares) curve fitting and a Hill slope of −1 or 1, respectively, to determine the IC 50 values and Michaelis-Menten kinetics shown in Figures 3 and 5 (see also Supplementary Figs. 4 and 5) . According to GraphPad tutorials, the calculated Michaelis-Menten values were transformed to generate double-reciprocal Lineweaver-Burke plots (Supplementary Fig. 4d-k) .
Mesenchymal stromal cell extraction, cultivation, characterization and differentiation. MSCs for two affected individuals and two unaffected, related controls were extracted from peripheral blood in heparin sulfate 48 . We determined that the frequency was 6% for successful MSC extraction from peripheral blood. Because the two controls were too old (>65 years), their MSCs did not demonstrate multilineage potential. The documented MSC controls used were extracted from the lipoaspirates of unaffected, unrelated family members. Fat biopsies were washed with 1% AntiAnti (Life Technologies) in PBS. Larger tissue was mechanically destructed using a scalpel, and the resulting suspension was washed with 1% AntiAnti in PBS over a 100-µm cell strainer. Subsequent PBS washing removed erythrocytes and blood. Homogenization was carried out by digestion with collagenase I (0.1% in PBS) with 1% BSA for 60 min at 37 °C. After 10 min of incubation with 15 ml of DMEM (low glucose), the adipocytes on the surface were removed. The remaining cell suspension was filtered again using a 100-µm cell strainer and centrifuged for 10 min at room temperature at 250g. After discarding the supernatant, the cell pellet was washed with 15 ml of DMEM and centrifuged again for 5 min. After centrifugation, the cells were resuspended in DMEM (low glucose) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2 IU/ml heparin sulfate, 5% human fresh-frozen plasma (FFP) and 5% concentrated thrombocytes. Depending on the volume of the lipoaspirate available, one of the following cultures was set up: 1 ml of cell suspension in a 25-cm 2 dish, up to 3 ml of cell suspension in a 75-cm 2 dish or more than 3 ml of cell suspension in a 150-cm 2 dish. After 24 h, the cells were washed five times with PBS, and new medium was added. After 3-4 d, stretched-out, fibroblast-like cells were observed. The splitting ratio for subconfluent MSCs was 1:5 or 1:6. Passages up to passage 8 were used in the described experiments. Upon FACS characterization for CD105 + , CD90 + , CD73 + , HLA-ABC + , CD31 − , CD34 − , CD45 − and HLA-DR − cells, MSCs were differentiated. The adipogenic differentiation medium constituted DMEM (1 g/l glucose), 1 IU/ml heparin sulfate, 1% concentrated thrombocytes, 5% FFP, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 µM dexamethasone, 100 µM l-ascorbic-2-phosphate, 60 µM indomethacin, 0.5 µM IBMX and 10 µM insulin (Sigma). After 2-5 weeks of differentiation, cells were fixed with steams of 40% formalin for 10 min, washed twice with distilled water and stained for 3 min in 1% oil red. The amount of time needed for differentiation was dependent on the presence of fatty vacuoles. Osteogenic differentiation was performed within 2 weeks. The differentiation medium for the first week contained DMEM (1 g/l glucose), 1 IU/ml heparin sulfate, 1% concentrated thrombocytes, 5% FFP, 100 U/ml penicillin, 100 µg/ml streptomycin, 10 nM dexamethasone and 100 µM l-ascorbic-2-phosphate. For the medium for the second week, 100 ng/ml recombinant human bone morphogenetic protein 2 (BMP2; R&D Systems) and 10 mM β-glycerophosphate were also added. After a PBS wash, cells were fixed with ice-cold methanol, air dried and stained with 0.5% Alizarin red for 30 s. After a 15-min PBS wash, calcium precipitates were microscopically documented. Chondrogenic differentiation was performed in micromass pellet cultures for up to 3 weeks. DMEM (4.5 g/l glucose) was supplemented with 1 IU/ml heparin sulfate, 5% FFP, 1× ITS-X, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 nM dexamethasone, 50 µM l-ascorbic-2-phosphate, 100 ng/µl recombinant human IGF-1, 10 ng/ml recombinant human TGF-β1 and 1 mM sodium pyruvate. Chondrogenic pellets were fixed overnight with 4% paraformaldehyde, and paraffin-embedded tissue was sectioned for toluidin blue staining. The smooth muscle differentiation medium contained DMEM (1 g/l glucose), 1 IU/ml heparin sulfate, 5% FFP, 100 U/ml penicillin, 100 µg/ml streptomycin and 1 ng/ml recombinant human TGF-β1. The medium was exchanged every 2 d for a period of 21 d.
FACS. FACS staining of extracellular surface markers was carried out according to standard procedures on a BD FACSCalibur. The following antibodies were used: antibody to CD105 (MHCD10504, Invitrogen), antibody to CD90 (555595, BD Biosciences), antibody to CD73 (550257, BD Biosciences), antibody to HLA-ABC (555552, BD Biosciences), antibody to CD31 (555445, BD Biosciences), antibody to CD34 (555821, BD Biosciences), antibody to CD45 (555482, BD Biosciences) and antibody to HLA-DR (555561, BD Biosciences).
Antibodies and immunoblotting.
After 48 h of transfection, HeLa cells were stimulated with either 20 µM forskolin or 100 ng/ml PMA for 30 min. Immunoblotting was performed according to standard protocols with 20 µg of total protein quantified by the BCA test (Thermo Scientific). Antibodies to PDE3A phosphorylated at Ser428 (S446B) and Ser438 (S442B) were ordered from the University of Dundee. C. MacKintosh validated the specificity of the antibodies and their usage in several projects 27, 28 . The following antibodies were also used: antibody to PDE3A (A302-740A, Bethyl Laboratories), antibody to PTHLH (ab41438, Abcam), antibody to PTHLH (ab115488, Abcam), antibody to β-tubulin (sc-9104, Santa Cruz Biotechnology), antibody to VASP phosphorylated at Ser157 (ab47268, Abcam), antibody to VASP (sc-13975, Santa Cruz Biotechnology), antibody to SMAα (ab8211, Abcam), antibody to calponin (ab700, Abcam), antibody to SM22α (ab10135, Abcam) and antibody to Renilla luciferase (MAB4400, Millipore). Competitors for the antibodies recognizing phosphorylated proteins were the appropriate peptides from Santa Cruz Biotechnology and the University of Dundee. Detection of Renilla luciferase, cotransfected into HeLa cells, indicated equal transfection and expression conditions. Blot signals were determined by horseradish peroxidase (HRP)-mediated chemiluminescence (SuperSignal West Pico, Thermo Scientific) and visualized in a PeqLab, Chemi-Smart 5000.
Immunofluorescence. For semiquantitative confocal microscopy to investigate proteins and their phosphorylation states, MSCs, VSMCs or transiently transfected HeLa cells were grown on glass coverslips. After one PBS wash, cells were fixed with fresh 4% paraformaldehyde for 10 min at room temperature and permeabilized with 80% methanol for 20 min at −20 °C. After blocking with 2% BSA in PBS and incubation with primary antibody at the appropriate dilution (see the antibodies listed in "Antibodies and immunoblotting"), staining was accomplished with Alexa Fluor 488-coupled secondary antibodies. Visualization was performed with a Bio-Rad MRC1024 attached to a Nikon Diaphot inverted microscope using the 488-nm line from an argon/krypton laser with a kalman filter of 3. After detection, the pseudocolors used indicated expression levels from black (low) to red (high).
Luciferase reporter assays. HeLa cells (5 × 10 4 ) were seeded 12-24 h before transfection. Equal molarities were used for transient transfection to compensate for the diverse plasmid sizes; 75 fmol each of the CRE-luciferase construct (pGL4.29, Promega) and the full-length wild-type PDE3A or full-length mutant constructs were cotransfected into cells with FuGENE Extreme Gene HP, according to the manufacturer's recommendations. The CRE-luciferase construct harbored a cAMP-responsive element that drove transcription of the luciferase gene. Thus, the measured luciferase activity was dependent on cellular cAMP levels. pRL-TK (12.5 ng; Promega) was added to control for transfection efficiency. After 48 h of transfection, either total RNA was prepared or cell lysates were analyzed using the Dual-Glo Assay (Promega) in a Berthold luminometer. Four hours before cell lysis, forskolin was added 23 . Forskolin activates adenylate cyclase for cAMP production. Forskolinmediated increased cAMP levels caused luciferase upregulation. l-arginine enhances guanylate cyclase activity for cGMP production and was added for 10-15 min before cell lysis 17 . Because cGMP inhibits PDE-mediated cAMP hydrolysis in a competitive manner, luciferase transcription was upregulated. In all functional in vitro experiments, DMSO served as the control. 
